The FDA accepted REZDIFFRA dependant on proof of efficacy from a medical demo, Trial 1, of 888 clients who experienced a liver biopsy showing inflammation resulting from NASH with average or advanced liver scarring, but not with cirrhosis from the liver. Tend not to share Rezdiffra with other peo